by Jason Heaviland | Feb 27, 2026
This data report showcases Discovery Exposomics results from a study examining chemical exposure patterns associated with Alzheimer’s disease. Using Panome Bio’s expansive database of more than 32,000 environmental and exposure-related compounds, the analysis provides...
by Jason Heaviland | Feb 27, 2026
This data report presents Targeted Exposomics findings from a study investigating chemical exposure patterns linked to Alzheimer’s disease. Using highly sensitive quantitative analysis, the report outlines exposure-related biomarkers, altered chemical profiles, and...
by Jason Heaviland | Feb 26, 2026
Our partners at Indiana University leveraged Next-Generation Metabolomics to profile metabolic and lipidomic changes in gingival crevicular fluid from healthy individuals and patients with periodontitis. Using dual LC-MS platforms and deep-learning–assisted data...
by Jason Heaviland | Feb 25, 2026
Advancing Untargeted Metabolomics Data Analysis with MassID™ MassID™ is Panome Bio’s identification engine for Next-Generation Metabolomics®, designed to turn complex untargeted metabolomics data into confident metabolite identifications. By evaluating detected...
by Jason Heaviland | Feb 24, 2026
MassID™ Turning Untargeted Data into Confident Discoveries Get a quick overview of how MassID enhances Panome Bio’s true untargeted metabolomics by transforming raw LC-MS/MS data into high-confidence, biologically interpretable metabolite profiles using advanced,...
